TOPIC

Biomedicine: Science

Related Topics:
Biomedicine: Science
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
A Chinese team of researchers loaded mast cells – which cause allergic symptoms when they encounter antigens such as seafood and pollen – with anticancer drugs to deliver them into tumours. Illustration: Shutterstock
Science

How Chinese scientists turn allergy into a powerful weapon against cancer

Mast cell platform can expand to carry other payloads, such as molecules, viruses, proteins and drug-loaded nanoparticles.

videocam
Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Science

Sperm quality decline: could easy-to-use balm from China solve the crisis?

In China, unhealthy lifestyles, pollution and work-related stress are cited in public health discussions around declining sperm quality.

videocam
A national reproductive health survey in 2021 indicated one in nearly six couples of childbearing age faced difficulties in starting a family. Photo: Getty Images
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.

Shenyang-based 3SBio is selling a 4.14 per cent stake in the company. Photo: Handout
Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

Hong Kong healthcare and hospitals

Hong Kong biotech firm to back controversial sanitary pad HPV test with evidence

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination despite government warning.

Dr Choi Pui-wah, founder of WomenX Biotech, also says she remains optimistic about Hong Kong as a tech destination. Photo: K. Y. Cheng
Biomedicine: Companies

China biotech forum bills antibody cancer drugs as next-generation treatment

Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies.

Antibody drug conjugates are targeted medicines that deliver chemotherapy agents to cancer cells. Photo: Shutterstock
Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Biomedicine: Companies

Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals

Two mainland biotech firms win global attention as Roche and Dianthus sign major licensing pacts, highlighting China’s growing role in next-generation drug development.

Biomedicine: Companies

Hong Kong MRI maker Time Medical seeks site to boost output, eyes IPO

Aiming to grow sales to US$300 million in 2027, the company is eyeing a Nasdaq IPO and then a Hong Kong secondary listing.

Ma Qiyuan, Time Medical Systems co-founder and chairman, pictured with one of the company’s scanners in its facility in Tai Po on October 6, 2025. Photo: Jonathan Wong
Biomedicine: Companies

Mirxes wins China’s approval to launch groundbreaking gastric cancer blood test

The non-invasive blood test helps in the early detection of the fifth leading cause of cancer deaths globally.

GastroClear, the first microRNA blood test approved in China for the early detection of gastric cancer, evaluates risks by detecting 12 miRNA biomarkers, according to developer Mirxes. Photo: Handout
Health & Fitness

Li Ka-shing-backed focused ultrasound therapy treats 1 millionth case

The therapy, which uses ultrasound energy to treat a number of diseases including cancer, is gaining global traction, a US expert says.

US-China relations

Opinion | Why US-China health and drugs cooperation must top Trump-Xi agenda

The years-long impasse harms both nations and the world, and the stakes in global health security could not be higher.

videocam
Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Ascletis trial shows drug candidate ASC47 boosts semaglutide weight loss effect

Chinese biotech firm is among dozens of mainland drug makers seeking to compete in the global market for diabetes and weight-loss drugs.

China’s weight-loss drugs market could grow to US$5.6 billion in 2035, according to Goldman Sachs. Photo: Shutterstock
US-China tech war

Chinese 3D biomolecule imaging start-up aims for IPO in 2027

Shuimu BioSciences is the first Chinese company to develop its own cryo-electron microscopy machine, a vital tool in drug discovery.

ETFs

Chinese biotech ETFs attract investors amid US$60 billion of licensing deals

Funds from the US are flowing into biotech ETFs as investors seek unique opportunities to beat the market, China AMC’s Heidi Cai says.

Biomedicine: Companies

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says

MGI’s latest product, the DNBSEQ-T7+, can sequence 144 human genomes a day, or one every 10 minutes.

MGI Tech’s DNA sequencers offer the best “comprehensive value” in terms of time, quality and cost, according to BGI Group CEO Yin Ye. Photo: Shutterstock
Hong Kong healthcare and hospitals

Hong Kong scientists developing new blood treatment to aid diabetes patients

Team of scientists aims to develop an injectable drug and hopes it can also be used to treat peripheral artery disease.

A doctor tests for loss of sensation in a diabetic patient’s feet. Photo: Getty Images
China technology

China’s biotech industry is gaining on the US. Can tariffs hold them back?

Pharmaceutical firms in China have grown fast, but geopolitics and a long head start could keep US-based leaders at industry apex - for now.

videocam
China manufacturing

China closes biotech gap with US as new drugs, pipelines top 30% of global total

Beijing has ramped up support for the bioeconomy with a five-year plan aimed at making the country a global leader by 2035.

China Future Tech briefing

Biomedicine | China goes big on weight-loss drugs in Novo, Eli Lilly challenge

Demand for anti-obesity drugs has expanded along with people’s waistlines, and Chinese companies are seeking to cash in with new treatments.

videocam
China goes big on weight-loss drugs in Novo, Eli Lilly challenge
Biomedicine: Industry Trends

Israeli pioneer in lab-grown kidneys seeks China biotech funding

The team has ‘a huge interest in Chinese and Hong Kong biotech companies’, says project lead Benjamin Dekel.

An Israeli hospital says it has achieved a breakthrough in cultivating kidneys in laboratories. Photo: AFP
China’s private sector

Why China’s top engineering academy has sights set on more private-sector blood

Adding more private enterprise executives and scientists to the Chinese Academy of Engineering is also expected to ‘influence the global flow of capital and talent’.

Biomedicine: Companies

China’s biomedicine sector takes off

China’s novel drug industry is experiencing a meteoric rise, fuelled by the increased development of new medicines and the prospect of many patents expiring.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement